---
title: Mendelian Randomization in Practice
subtitle: AFGen Fellows Lecture Series
author: Anish S. Shah, MD, MS
institute: Division of Cardiology, Department of Medicine, University of Illinois Chicago 
date: April 24, 2024
format:
  revealjs:
    transition: fade
    transition-speed: fast
    slide-number: true
    incremental: true
    auto-animate-easing: ease-in-out
    auto-animate-unmatched: false
    progress: true
    chalkboard: true
    height: 1080
    width: 1920

revealjs-plugins:
  - attribution

csl: ../../apa.csl
---

# Introduction

---

::: {.callout-important title="Paper"}
Björnson, Elias, Martin Adiels, Marja-Riitta Taskinen, Stephen Burgess, M. John Chapman, Chris J. Packard, and Jan Borén. 
[Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis]{.red}
Journal of the American College of Cardiology 83, no. 3 (January 23, 2024): 385–95. 
https://doi.org/10.1016/j.jacc.2023.10.039.
:::

. . .

:::: {.columns}
::: {.column width="50%"}
Question:

- Are Lp(a) and LDL equivalent in their atherogenicity?
:::
::: {.column width="50%"}
Approach:

- Using ApoB as a quantification of particles, assess genetic contribution to Lp(a) and LDL and the subsequent CVD risk
:::
::::


## Objectives

a. Review the role of lipids in atherosclerosis
a. Understand the effect of genetic variants on lipid particles
a. Describe the principles of mendelian randomization
a. Consider the intersection of epidemiology/causality using this methodology

## Outline

1. An overview of lipids
1. (Re)-introduction to mendelian randomization
1. Review of the findings from the paper by @Bjornson2024

# Background on Lipids

# Mendelian Randomization

# Findings

---

![Relative atherogenicity of Lp(a) and LDL particles](bjornson-2024-central-illustration.png){#fig-central}

::: attribution
@Bjornson2024
:::

---

![Effect of SNP clusters on plasma apoB and Lp(a) levels](bjornson-2024-snp-clusters-lpa.png){#fig-snp}

::: attribution
@Bjornson2024
:::

---

![Relationship of CHD risk to apoB from LDL and Lp(a)](bjornson-2024-chd-risk-by-apob-type.png){#fig-chd}

::: attribution
@Bjornson2024
:::

---

![Odds for CVD by genetic prediction of variation in apoB](bjornson-2024-odds-ratio.png){#fig-odds}

::: attribution
@Bjornson2024
:::

---

![Relative atherogenicity of Lp(a) and LDL associated apoB](bjornson-2024-relative-atherogenicity.png){#fig-relative}

::: attribution
@Bjornson2024
:::

---

![ApoB and CHD risk by polygenic scores](bjornson-2024-chd-risk-pgs.png){#fig-pgs}

::: attribution
@Bjornson2024
:::

## References {.smallest}

::: {#refs}
:::